Conventional COPD medications also come with side effects, such as increased heart rate and dry mouth from bronchodilators, ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Triple therapy inhalers are expected to account for 11.3% of the total market. The chronic obstructive pulmonary disease ...

Long-distance caregivers can help manage a loved one’s finances, organize their medical appointments, coordinate with other ...

Climate change is affecting the health of all individuals and represents an even more significant health risk for individuals with COPD.

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...